Could a cancer drug tame multiple sclerosis? new trial launches
NCT ID NCT03783416
First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 27 times
Summary
This study is testing whether a drug called ixazomib, which is already used for a type of cancer, is safe for people with multiple sclerosis (MS). The drug targets certain immune cells that may drive MS. About 72 adults with relapsing-remitting or progressive MS will take either ixazomib or a placebo for up to two years. The main goal is to check for side effects, but researchers will also look for signs that the drug might reduce disease activity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING REMITTING MULTIPLE SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Royal London Hospital, Barts Health NHS Foundation Trust
RECRUITINGLondon, Greater London, E1 1BB, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.